On August 26, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, reported that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Details:

Citi’s 2026 Biopharma Back to School Conference (New York, NY)
Date/Time: Wednesday, September 9, 2026, at 10:00AM ET
Webcast Link: Citi / Candel Fireside Chat

2026 Cantor Global Healthcare Conference (New York, NY)
Date/Time: Thursday, September 10, 2026, at 3:20PM ET
Webcast Link: Cantor / Candel Fireside Chat

H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)
Date/Time: Tuesday, September 15, 2026, at 9:30AM ET
Webcast Link: H.C. Wainwright / Candel Fireside Chat

Live webcasts of the presentations will be available by selecting Events & Presentations in the Investors section of Candel’s website at www.candeltx.com. Webcast replays will be archived for up to 90 days following the session date.

(Press release, Candel Therapeutics, AUG 26, 2026, View Source [SID1234670354])